Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 monotherapy study of LY2157299 in lower-risk myelodysplastic syndromes
2013-003235-30Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of galunisertib in myelodysplastic syndrome (MDS), sponsored by Eli Lilly and Company. Primary endpoint: Primary endpoint (Phase 2). Started Nov 2013; status: completed.
02
Drugs
galunisertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2013-003235-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003235-30.